menu search

Ocugen, inc. announces submission of investigational new drug application with u.s. fda to initiate a phase 1 clinical trial evaluating ocu200 for the treatment of diabetic macular edema

MALVERN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on d...

February 27, 2023, 10:57 pm


Search within

Pages Search Results: